Zach shares his insights on the contrasting motivations behind IPOs in tech and biotech, emphasizing that while tech companies often seek liquidity, biotech firms primarily aim to raise funds for trials. He highlights the speculative nature of recent biotech IPOs, which have occurred without solid data, leading to many trading below their initial prices. Ultimately, he believes that strong data is crucial for success in the biotech space.
